The North America In Vivo Toxicology Market was valued at USD 718.5 Million in 2025 and is expected to reach USD 1,287.4 Million by 2035, growing at a CAGR of 5.6% from 2024 to 2035. This market is driven by advanced biomedical research activities, increasing drug development demands, and heightened regulatory scrutiny.
The economic impact of tariffs on "North America In Vivo Toxicology Market".
Market Growth Drivers
Rising Pharmaceutical R&D Investments: Key companies such as Charles River Laboratories are boosting investments in pharmaceutical research and development. The demand to perform early toxicity testing in drug pipelines is growing, fueled by the need to detect potential adverse effects at the earliest stage. As a result, both CROs and biopharma companies are increasing outsourcing of in vivo toxicology services, accelerating market growth.
Stringent Regulatory Requirements: The enforcement of strict regulatory protocols by agencies such as the FDA and Health Canada necessitate comprehensive in vivo toxicology testing for any new therapeutic or chemical entity. Companies like Covance (a LabCorp subsidiary) are expanding their service offerings to comply with guidelines, ensuring that drugs and chemicals undergo robust safety assessments before approval for market entry.
Latest Market Trends
Adoption of AI & Digital Technology: Companies such as Envigo are increasingly deploying data analytics, artificial intelligence, and digital tracking tools to enhance the accuracy of in vivo studies. AI-enabled protocols are helping in the real-time monitoring of animal models, improving data collection efficiency, and reducing errors in toxicological assessments.
Growth of Early Phase Toxicology Services: There is a clear upward trend in demand for early phase and preclinical in vivo toxicology services, particularly for oncology and gene therapy drugs. Major CROs including Charles River Laboratories are expanding preclinical study capabilities to support biotechs seeking rapid advancement of drug candidates under tighter development timelines.
Market Opportunity
Expansion of Biologics and Biosimilars Pipeline: Companies such as Labcorp and Charles River are well-positioned to capitalize on the increasing R&D pipeline of biologics and biosimilars, necessitating in vivo toxicological evaluations to ensure product safety.
Integration of Advanced Imaging: Incorporation of advanced imaging modalities in in vivo assessments presents a lucrative opportunity. CROs offering multimodal imaging solutions alongside toxicological services can attract pharmaceutical partners looking for comprehensive and precise data.
North America In Vivo Toxicology Market Revenue (USD Million), 2020-2035
The accompanying chart illustrates consistent and robust growth of the North American In Vivo Toxicology market from 2020 to 2035. Starting at USD 520 Million in 2020, the market demonstrated steady annual increments, reaching USD 718.5 Million in 2025. The growth trajectory remains upward with accelerated increases, culminating in USD 1,287.4 Million by 2035. This expansion is attributed to rising demand for drug development and regulatory compliance, and further supported by increased adoption of digital and data-driven solutions by service providers.
North America In Vivo Toxicology Market Share by Region (%) in 2025
The pie chart analysis reveals that the United States leads the North America In Vivo Toxicology market in 2025 with a commanding 75% share, reflecting its robust R&D infrastructure and high pharmaceutical expenditures. Canada follows with 15%, benefiting from substantial biotech investments and favorable regulatory support. Mexico, though smaller, holds a 6% share as its pharma and CRO sectors grow. The remaining 4% is distributed amongst other NAFTA-associated and Caribbean regions, emphasizing the strong dominance of the US in the market.
Recent Developments in North America In Vivo Toxicology Market
In February 2024, Charles River Laboratories launched an expanded toxicology platform integrating advanced in vivo imaging modalities with AI-powered analytics, aiming to enhance the quality of preclinical safety assessments and reduce study timelines. This initiative is expected to expedite early phase R&D for their pharmaceutical and biotech clients.
In April 2024, Labcorp (Covance) announced the construction of a new state-of-the-art preclinical toxicology research facility in Texas. The new site underscores the company’s commitment to expanding its North American capabilities and will deliver specialized in vivo toxicity testing for gene and cell therapy products, as the demand in these segments accelerates.
In March 2024, Envigo finalized a strategic partnership with a major Canadian biotechnology firm to deliver cross-border in vivo toxicity studies. The agreement focuses on leveraging Envigo’s digital monitoring solutions to enhance reproducibility and compliance for novel biologics entering first-in-human trials, thereby expanding the company’s footprint in Canada.
Press Releases